Roberto Barriales Villa

List of Publications by Year in Descending Order

106 papers	1,223 citations	18 h-index	33 g-index
120 ext. papers	1,808 ext. citations	3.6 avg, IF	3.73 L-index

#	Paper	IF	Citations
106	Selección de lo mejor del año 2021 en cardiopatías familiares y genética cardiovascular. *REC: CardioClinics*, **2022**, 57, S54-S59	0.2	
105	Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease.. *PLoS ONE*, **2022**, 17, e0263140	3.7	4
104	Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy.. *Circulation: Arrhythmia and Electrophysiology*, **2022**, CIRCEP121010075	6.4	0
103	Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic´Cardiomyopathy.. *Journal of the American College of Cardiology*, **2022**, 79, 1986-1997	15.1	1
102	Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. *Journal of the American College of Cardiology*, **2021**, 78, 1682-1699	15.1	5
101	Clinical utility of genetic testing in patients with dilated cardiomyopathy. *Medicina Clínica*, **2021**, 156, 485-495	1	1
100	Predictores de riesgo en una cohorte española con cardiolaminopatías. Registro REDLAMINA. *Revista Espanola De Cardiologia*, **2021**, 74, 216-224	1.5	8
99	The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy. *European Journal of Preventive Cardiology*, **2021**,	3.9	9
98	Light chain and transthyretin cardiac amyloidosis: Clinical characteristics, natural history and prognostic factors. *Medicina Clínica (English Edition)*, **2021**, 156, 369-378	0.3	
97	Light chain and transthyretin cardiac amyloidosis: Clinical characteristics, natural history and prognostic factors. *Medicina Clínica*, **2021**, 156, 369-378	1	2
96	Correlación genotipo-fenotipo en miocardiopatía hipertrófica: un estudio multicéntrico en Portugal y España sobre la variante p.Arg21Leu de TPM1. *Revista Espanola De Cardiologia*, **2021**, 75, 242-242	1.5	0
95	Clinical utility of genetic testing in patients with dilated cardiomyopathy. *Medicina Clínica (English Edition)*, **2021**, 156, 485-495	0.3	
94	Miocardiopatía dilatada y distrofia muscular de cinturas leve causada por la variante genética p.Gly424Ser en fukutina. *Revista Espanola De Cardiologia*, **2021**, 74, 987-987	1.5	
93	Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy. *European Journal of Heart Failure*, **2021**, 23, 1276-1286	12.3	7
92	Shprintzen-Goldberg syndrome and aortic dilatation: apropos of 2 new cases. *Revista Espanola De Cardiologia (English Ed)*, **2021**, 74, 551-553	0.7	
91	Author?s reply: Prognostic implication of exercise echocardiography in patients with hypertrophic cardiomyopathy, by Teruhiko Imamura. *Journal of Cardiology*, **2021**, 77, 677-678	3	
90	Risk predictors in a Spanish cohort with cardiac laminopathies. The REDLAMINA registry. *Revista Espanola De Cardiologia (English Ed)*, **2021**, 74, 216-224	0.7	1

89	Incidental finding of cornea verticillata or lamellar inclusions in kidney biopsy: measurement of lyso-Gb3 in plasma defines between Fabry disease and drug-induced phospholipidosis. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2021**, 1867, 165985	6.9	
88	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. *European Heart Journal Quality of Care & Clinical Outcomes*, **2021**, 7, 134-142	4.6	0
87	Síndrome de Shprintzen-Goldberg y dilatación aórtica: a propósito de dos nuevos casos. *Revista Espanola De Cardiologia*, **2021**, 74, 551-553	1.5	
86	Lamin cardiomyopathies risk stratification. *Europace*, **2021**, 23, 487	3.9	1
85	Value of a comprehensive exercise echocardiography assessment for patients with hypertrophic cardiomyopathy. *Journal of Cardiology*, **2021**, 77, 525-531	3	1
84	Selección de lo mejor del año 2020 en cardiopatías familiares y genética cardiovascular. *REC: CardioClinics*, **2021**, 56, 9-14	0.2	
83	Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: the ESC EORP Cardiomyopathy/Myocarditis Registry. *European Heart Journal Cardiovascular Imaging*, **2021**, 22, 781-789	4.1	2
82	Genotype-phenotype correlations in hypertrophic cardiomyopathy: a multicenter study in Portugal and Spain of the TPM1 p.Arg21Leu variant. *Revista Espanola De Cardiologia (English Ed)*, **2021**, 75, 242-242	0.7	
81	Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2021**, 77, 922-936	15.1	26
80	Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy. *Journal of Biological Chemistry*, **2021**, 297, 100854	5.4	5
79	Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure. *JAMA Cardiology*, **2021**, 6, 891-901	16.2	7
78	Clinical Risk Prediction in Patients With Left Ventricular Myocardial Noncompaction. *Journal of the American College of Cardiology*, **2021**, 78, 643-662	15.1	7
77	Prognostic implications of pathogenic truncating variants in the TTN gene. *International Journal of Cardiology*, **2020**, 316, 180-183	3.2	1
76	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. *Journal of the American College of Cardiology*, **2020**, 76, 186-197	15.1	16
75	Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the Gene. *Circulation: Heart Failure*, **2020**, 13, e006832	7.6	24
74	The p.(Cys150Tyr) variant in CSRP3 is associated with late-onset hypertrophic cardiomyopathy in heterozygous individuals. *European Journal of Medical Genetics*, **2020**, 63, 104079	2.6	2
73	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet, The*, **2020**, 396, 759-769	40	149
72	Primer caso descrito de enfermedad de Fabry causada por un mosaicismo somático en el gen GLA. *Revista Espanola De Cardiologia*, **2019**, 72, 585-587	1.5	1

71	Cardiac-only Timothy Syndrome (COTS): Peripartum Cardiomyopathy and Long QT Syndrome. *Revista Espanola De Cardiologia (English Ed)*, **2019**, 72, 876-878	0.7	1
70	Cambio de paradigma en el diagnóstico y tratamiento de la amiloidosis cardiaca por transtirretina. *REC: CardioClinics*, **2019**, 54, 9-12	0.2	1
69	First Reported Case of Fabry Disease Caused by a Somatic Mosaicism in the GLA Gene. *Revista Espanola De Cardiologia (English Ed)*, **2019**, 72, 585-587	0.7	2
68	Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). *JAMA Cardiology*, **2019**, 4, 918-927	16.2	67
67	Negative screening of Fabry disease in patients with conduction disorders requiring a pacemaker. *Orphanet Journal of Rare Diseases*, **2019**, 14, 170	4.2	2
66	Clasificación de la hipertensión arterial pulmonar basada en el estudio genético y familiar. *Revista Espanola De Cardiologia*, **2019**, 72, 591-593	1.5	
65	Síndrome de Timothy exclusivamente cardiaco (COTS): miocardiopatía periparto y QT largo. *Revista Espanola De Cardiologia*, **2019**, 72, 876-878	1.5	1
64	Mitral Repair as a Treatment of Outflow Tract Obstruction in Hypertrophic Cardiomyopathy: "Myectomy Without Myectomy". *Revista Espanola De Cardiologia (English Ed)*, **2019**, 72, 266-268	0.7	
63	Letter by Barriales-Villa et al Regarding Article, "Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies". *Circulation*, **2019**, 140, e818-e819	16.7	2
62	Classification of Pulmonary Arterial Hypertension by Genetic and Familial Testing. *Revista Espanola De Cardiologia (English Ed)*, **2019**, 72, 591-593	0.7	
61	Isolated right ventricle endomyocardial fibrosis. An increasingly frequent disease in Spain. *Medicina Clínica*, **2019**, 153, 219-220	1	
60	The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy. *European Heart Journal*, **2019**, 40, 1671-1677	9.5	15
59	Tratamiento de la obstrucción del tracto de salida en la miocardiopatía hipertrófica mediante reparación mitral: «miectomía sin miectomía». *Revista Espanola De Cardiologia*, **2019**, 72, 266-268	1.5	
58	Multidisciplinary units, a key element in the study and prevention of sudden cardiac death caused by inherited cardiac conditions. *Spanish Journal of Legal Medicine*, **2018**, 44, 46-52	0.4	0
57	The p.Arg118Cys Variant in the GLA Gene Does Not Cause Fabry Disease. More Evidence. *Revista Espanola De Cardiologia (English Ed)*, **2018**, 71, 871-873	0.7	1
56	Unidades multidisciplinares en el estudio y prevención de la muerte súbita por cardiopatías familiares. *Revista Espanola De Medicina Legal*, **2018**, 44, 46-52	0.2	1
55	The importance of genotype-phenotype correlation in the clinical management of Marfan syndrome. *Orphanet Journal of Rare Diseases*, **2018**, 13, 16	4.2	23
54	Storage diseases with hypertrophic cardiomyopathy phenotype. *Global Cardiology Science & Practice*, **2018**, 2018, 28	0.7	3

53	La variante p.Arg118Cys en el gen GLA no causa enfermedad de Fabry. Más evidencias. *Revista Espanola De Cardiologia*, **2018**, 71, 871-873	1.5	2
52	Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. *Journal of the American College of Cardiology*, **2018**, 72, 2457-2467	15.1	33
51	Dilated Cardiomyopathy Due´to´BLC2-Associated Athanogene´3´(BAG3)´Mutations. *Journal of the American College of Cardiology*, **2018**, 72, 2471-2481	15.1	53
50	Isogenic Pairs of hiPSC-CMs with Hypertrophic Cardiomyopathy/LVNC-Associated ACTC1 E99K Mutation Unveil Differential Functional Deficits. *Stem Cell Reports*, **2018**, 11, 1226-1243	8	31
49	Letter by Ruiz-Guerrero et al Regarding Article, "Yield of the RYR2 Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation". *Circulation Genomic and Precision Medicine*, **2018**, 11, e002159	5.2	1
48	Nueva mutación fundadora en MYBPC3: comparación fenotípica con la mutación de MYBPC3 más frecuente en España. *Revista Espanola De Cardiologia*, **2017**, 70, 105-114	1.5	17
47	Miocardiopatía hipertrófica sin hipertrofia ventricular: utilidad del estudio anatomopatológico y genético en la prevención de la muerte súbita. *Revista Espanola De Cardiologia*, **2017**, 70, 604-606	1.5	2
46	Extensa familia con síndrome de Marfan en´la´que se´demuestra la´patogenicidad de una´variante «sinónima» (p.Ile2118=) en el gen de la fibrilina 1. *Revista Espanola De Cardiologia*, **2017**, 70, 679-681	1.5	4
45	Large Family With Marfan Syndrome Demonstrating the Pathogenicity of a "Synonymous" Variant (p.Ile2118=) in the Fibrillin-1 Gene. *Revista Espanola De Cardiologia (English Ed)*, **2017**, 70, 679-681	0.7	
44	Hypertrophic Cardiomyopathy Without Ventricular Hypertrophy: Usefulness of Genetic and Pathological Study in Preventing Sudden Death. *Revista Espanola De Cardiologia (English Ed)*, **2017**, 70, 604-606	0.7	1
43	A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain. *Revista Espanola De Cardiologia (English Ed)*, **2017**, 70, 105-114	0.7	3
42	Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. *International Journal of Cardiology*, **2017**, 248, 232-238	3.2	31
41	¿Cómo enfrentarse a una sospecha clínica de amiloidosis cardíaca? Un enfoque práctico para el diagnóstico. *Cardiocore*, **2017**, 52, 27-34		3
40	Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. *Journal of the American College of Cardiology*, **2016**, 68, 2440-2451	15.1	213
39	La importancia del estudio familiar y genético: la mutación p.L3778F en el receptor de la rianodina probablemente no cause un fenotipo tan grave. *Revista Espanola De Cardiologia*, **2016**, 69, 702-704	1.5	1
38	The Importance of Family-genetic Screening: The Phenotype Caused by the p.L3778F Ryanodine Receptor Mutation is Likely Less Severe Than Previously Thought. *Revista Espanola De Cardiologia (English Ed)*, **2016**, 69, 702-4	0.7	
37	Plan of Action for Inherited Cardiovascular Diseases: Synthesis of Recommendations and Action Algorithms. *Revista Espanola De Cardiologia (English Ed)*, **2016**, 69, 300-9	0.7	9
36	Protocolo de actuación en las cardiopatías familiares: síntesis de´recomendaciones y´algoritmos de´actuación. *Revista Espanola De Cardiologia*, **2016**, 69, 300-309	1.5	42

35	Calmodulin 2 Mutation N98S Is Associated with Unexplained Cardiac Arrest in Infants Due to Low Clinical Penetrance Electrical Disorders. *PLoS ONE*, **2016**, 11, e0153851	3.7	18
34	Phenotype and prognostic correlations of the converter region mutations affecting the myosin heavy chain. *Heart*, **2015**, 101, 1047-53	5.1	34
33	Genetics of cardiomyopathies: novel perspectives with next generation sequencing. *Current Pharmaceutical Design*, **2015**, 21, 418-30	3.3	14
32	Non-Atherosclerotic Coronary Artery Disease **2015**, 155-169		
31	Usefulness of genetic diagnosis in a woman with hypertrophic cardiomyopathy and the desire for motherhood: information is key. *Revista Espanola De Cardiologia (English Ed)*, **2014**, 67, 333-4	0.7	
30	Utilidad del diagnstico genico en la miocardiopata hipertrfica de una mujer que desea ser madre: la informacin es clave. *Revista Espanola De Cardiologia*, **2014**, 67, 333-334	1.5	
29	Los estudios genicos en la prevencin de la muerte sbita: ¿realidad o ficcin?. *Cardiocore*, **2012**, 47, 50-53		0
28	Genica del sndrome de Marfan. *Cardiocore*, **2011**, 46, 101-104		1
27	The interpretation of genetic tests in inherited cardiovascular diseases. *Neurology International*, **2011**, 1, 8	0	9
26	Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. *European Heart Journal*, **2011**, 32, 177-83	9.5	16
25	Sndrome de Brugada. *Revista Espanola De Cardiologia*, **2010**, 63, 620	1.5	
24	Trastornos graves de la conduccin cardiaca e implante de marcapasos en pacientes con miocardiopata hipertrfica. *Revista Espanola De Cardiologia*, **2010**, 63, 985-988	1.5	16
23	P2Pmuch mitral tissue. *European Heart Journal Cardiovascular Imaging*, **2010**, 11, 189	4.1	
22	Screening mutations in myosin binding protein C3 gene in a cohort of patients with Hypertrophic Cardiomyopathy. *BMC Medical Genetics*, **2010**, 11, 67	2.1	20
21	Prevalence and outcome of newly detected diabetes in patients who undergo percutaneous coronary intervention. *European Heart Journal*, **2009**, 30, 2614-21	9.5	41
20	A homozygous MYBPC3 gene mutation associated with a severe phenotype and a high risk of sudden death in a family with hypertrophic cardiomyopathy. *Revista Espanola De Cardiologia (English Ed)*, **2009**, 62, 572-5	0.7	7
19	Mutacin en homocigosis en el gen MYBPC3 asociada a fenotipos severos y alto riesgo de muerte sbita en una familia con miocardiopata hipertrfica. *Revista Espanola De Cardiologia*, **2009**, 62, 572-575	1.5	12
18	Miocardiopata producida por feocromocitoma o miocardiopata por estrs secundaria a feocromocitoma: ¿necesidad de una nueva denominacin?. *Revista Espanola De Cardiologia*, **2008**, 61, 432-433	1.5	7

17	Pheochromocytoma-Related Cardiomyopathy or Stress Cardiomyopathy Secondary to Pheochromocytoma: Is New Terminology Needed?. *Revista Espanola De Cardiologia (English Ed)*, **2008**, 61, 432-433	0.7	
16	Apical hypertrophic cardiomyopathy and left ventricular non-compaction: two faces of the same disease. *Heart*, **2008**, 94, 1253	5.1	7
15	Anomalous Coronary Arteries Originating in the Contralateral Sinus of Valsalva: Registry of Thirteen Spanish Hospitals (RACES). *Revista Espanola De Cardiologia (English Ed)*, **2006**, 59, 620-623	0.7	1
14	Congenital Coronary Artery Anomalies With Origin in the Contralateral Sinus of Valsalva: Which Approach Should We Take?. *Revista Espanola De Cardiologia (English Ed)*, **2006**, 59, 360-370	0.7	
13	Anomalías congénitas de las arterias coronarias con origen en el seno de Valsalva contralateral: ¿qué actitud se debe seguir?. *Revista Espanola De Cardiologia*, **2006**, 59, 360-370	1.5	21
12	Registro de anomalías congénitas de las arterias coronarias con origen en el seno de Valsalva contralateral en 13 hospitales españoles (RACES). *Revista Espanola De Cardiologia*, **2006**, 59, 620-623	1.5	17
11	Congenital coronary artery anomalies in the adult: a new practical viewpoint. *Clinical Cardiology*, **2005**, 28, 359; author reply 359	3.3	
10	Síndrome de discinesia apical transitoria sin lesiones coronarias: importancia del gradiente intraventricular. *Revista Espanola De Cardiologia*, **2004**, 57, 85-88	1.5	10
9	Transient Left Ventricular Apical Ballooning Without Coronary Stenoses Syndrome: Importance of the Intraventricular Pressure Gradient. *Revista Espanola De Cardiologia (English Ed)*, **2004**, 57, 85-88	0.7	
8	Bicuspid aortic valve and coronary anomalies. *Circulation*, **2003**, 107, e105; author reply e105	16.7	10
7	Transient left ventricular apical ballooning and outflow tract obstruction. *Journal of the American College of Cardiology*, **2003**, 42, 1143-4; author reply 1144	15.1	30
6	Coronary anomalies. *Circulation*, **2003**, 107, E36-6; author reply E36-6	16.7	3
5	Treatment of hypertrophic cardiomyopathy. *Circulation*, **2003**, 107, e110; auhor reply e110	16.7	1
4	Apical hypertrophic cardiomyopathy, intraventricular pressure gradients and ST segment elevation. *International Journal of Cardiology*, **2002**, 82, 179-80	3.2	3
3	Usefulness of helical computed tomography in the identification of the initial course of coronary anomalies. *American Journal of Cardiology*, **2001**, 88, 719	3	17
2	Do racial or populational differences exist in coronary anomalies?. *International Journal of Cardiology*, **2001**, 81, 89-90	3.2	0
1	Protein haploinsufficiency drivers identify MYBPC3 mutations that cause hypertrophic cardiomyopathy		2